About Us

Curriculum

Michelle Terez Pelle, M.D., FAAD
Primary Office Address

MedDerm Associates, Inc.
501 Washington St. Suite 502, 5th Fl
San Diego, CA 92103
www.MedDerm.net

Education

1989-93 BA Franklin and Marshall College
Lancaster, PA
(Biology, Chemistry)

1993-97 MD Jefferson Medical College of
Thomas Jefferson University
Philadelphia, PA

Postgraduate Training and Fellowship Appointments

1997-98 Internal Medicine Internship
University of Pittsburgh Medical Center
Pittsburgh, PA

1998-01 Dermatology Residency
Geisinger Medical Center
Danville, PA

2001-02 Clinician Educator Fellowship
Hospital of the University of Pennsylvania
Philadelphia, PA

Masters Level Coursework

1. Patient Oriented Research I.
CREST Program, UCSD Medical Center, Spring, 2005
• developed and applied the theories of clinical trial design and analysis
• discussed the practical issues of financing and implementation of clinical trials
• described issues of monitoring trials and worked in cooperative groups
• designed a protocol for a clinical trial

2. Clinical Epidemiology I.
University of Pennsylvania, Fall Semester, 2001

Staff Appointments

Instructor:
July, 2001 – June, 03 Hospital of the University of Pennsylvania
July, 2001 – June, 03 Pennsylvania Hospital, Philadelphia
July, 2001 – June, 03 Presbyterian Medical Center, Philadelphia

Assistant Clinical Professor:
July, 2003 – June, 2004 Boston University Medical Center
July, 2003 – June, 2004 Boston Veteran Affairs Medical Center
July, 2004 – June, 2006 Veterans Administration, San Diego
Aug, 2004 – Jan, 2010 Univ. of California, San Diego Medical Center

Current Appointments:
May, 2007 to present Scripps Mercy Medical Center, San Diego
Staff Dermatologist

Specialty Certification

2001 – 2009 Board Certification, American Board of Dermatology
2009 – 2021 Recertification, American Board of Dermatology

Licensure

1997 – 2003 Pennsylvania (inactive)
2003 – 2005 Massachusetts (inactive)
2004 – present California (active)

Awards and Honors

2007 Robert W. Goltz M.D. Excellence in Teaching Award, UCSD Medical Center Division of Dermatology

2004 Dermatology Basic Science Lecturer of the Year, Boston University Dermatology

2003 Leadership Forum of American Academy of Dermatology

2002 Irish Association of Dermatology Scholarship
Guest Attendance at 2003 Annual Meeting

2001 Women’s Dermatology Society Scholarship
Funded Mentorship with Dr. Jeffrey P. Callen

1994 Leon Herbin Scholarship for Academic Merit
Franklin and Marshall College

1992 Huffnagle Scholarship for Academic Merit
Franklin and Marshall College

Membership in Professional Societies

National Societies:
American Academy of Dermatology
Medical Dermatology Society
American Society of Mohs Surgery

Editorial Positions

2001-09 Emedicine Online Journal, Dermatology Section

2007-10 DermClips Associate Editor, American Academy of Dermatology

Academic Committees and Titles

2004-06 Course Director, Medicine 428 Elective, “Clinical Dermatology” UCSD School of Medicine

2003-04 Course Director, 4th Year Medical Student Elective, “Clinical Dermatology”, Boston University School of Medicine

2002-06 American Board of Dermatology Recertification Board Committee, American Academy of Dermatology

2001-02 Graduate Medical Education Committee,
Hospital of the University of Pennsylvania

Bibliography

Publications, peer reviewed:
Jackson JM, Pelle M. Topical rosacea therapy: the importance of
vehicles for efficacy, tolerability and compliance. J Drugs Dermatol 2011;10:627-33.
Kempiak S, Lee P, Pelle MT. Rhinophyma treated with cryosurgery. Dermatol Surg, 2009; 35(3): 543-5.

Lesesky EB, Pelle MT, O'Grady TC. Diffuse nodules in a woman with renal failure: chronic tophaceous gout. Arch Dermatol 2007;143:1201-6.

Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol 2004;51:499-512.

Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis and subtype classification. J Am Acad Dermatol 2004;51:327-41.

Reich HL, Crawford GH, Pelle MT, James WD. Group B Streptococcal Toxic Shock-like Syndrome. Arch Dermatol; 2004:140:163-6.

Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002;138:1231-33.

Pelle MT, Tyler WB, Pride HB. Clinical Review: Eccrine angiomatous hamartoma. J Am Acad Dermatol 2002;47:429-35.

Pelle MT, Miller OF. Dermatologic manifestations and management of vascular steal syndrome in hemodialysis patients with arteriovenous fistulas. Arch Dermatol 2002;138:1296-98.

Pelle MT, Miller OF. Debridement of necrotic eschar with 40% urea speeds healing of residual limbs and prevents further surgery. Arch Dermatol 2001;137:1288-90.

Mowad CM, Pelle M, Elenitsas R. Laugier-Hunziker Syndrome. In: James WD, Elston D. (Chief Eds.); eMedicine Dermatology. St. Petersburg: eMedicine Corporation, 2000.

Anderson CK, Mowad CM, Goff ME, Pelle MT. Bullous pemphigoid arising in surgical wounds. Brit J Dermatol 2001;145:670-672.

Chapters and Reviews:
Pelle MT. Rosacea. Fitzpatrick’s Dermatology in General Medicine, 2012, 8th Ed. Chap 81. Wolff K, Goldsmith L, Katz S, Gilchrest BA, Paller AS and Leffell D, Editors. McGraw Hill Publishing, pp.918-925.

Pelle MT. Rosacea. Fitzpatrick’s Dermatology in General Medicine, 2008, 7th Ed. Chap 79. Wolff K, Goldsmith L, Katz S, Gilchrest BA, Paller AS and Leffell D, Editors. McGraw Hill Publishing, pp.703-709.

Pelle MT. Drugs for the Skinternist. Dermatologic Drug Therapy.2007, 2nd Ed. Chap 27. Wolverton, S. Editor, Elsevier, Inc. pp. 501-522.

Pelle MT. Issues and Advances in Cutaneous Lupus Erythematosus. Adv Dermatol 2006;22:55-65. James WD, Cockerell CJ, Maloney ME, Paller AS, Yancey KB, Editors. Mosby Publishing.

Pelle MT. Rosacea Management: An Inside Look at Topical Therapy. Practical Dermatol 2005;2(4):32-36.

Pelle MT. Rosacea Therapy Update. Advances in Dermatology, Vol 19, 2003, pp 139-70.

Pelle MT, Werth VP. Cutaneous Vasculitis. In press, Conn’s Current Therapy, 56th Ed., 2003, W. B. Saunders Co.

Pelle MT, Werth VP. Thalidomide in Cutaneous Lupus Erythematosus. Amer J Clin Dermatol 2003; 4(6):379-87.

Lectures and Presentations

Psoriasis Therapy Update. Guest Lecturer, National Psoriasis Foundation, San Diego Chapter, Continuing Education Series, “Psoriasis: More Than Skin Deep”. Doubletree Hotel, Del Mar, CA, September 24, 2011.

Tough Cases – Medical Dermatology Forum. Guest Lecturer, UCSD Dermatology Grand Rounds, UCSD Medical Center, San Diego, CA, June 24, 2010.

Dermatologic Manifestations on the Lower Extremities, Topics and Advances in Internal Medicine, Lecturer, Annual CME Course, Department of Medicine, UCSD Medical Center. San Diego, CA, March 6, 2010.

Hair Loss, Hair Removal and Hair Restoration in Women
, Topics and Advances in Internal Medicine, Lecturer, Annual CME Course, Department of Medicine, UCSD Medical Center. San Diego, CA, March 10, 2009.

Introduction to Patch Testing, Topics and Advances in Internal Medicine, Lecturer, Annual CME Course, Department of Medicine, UCSD Medical Center. San Diego, CA, March 10, 2009.

The New UV: Applications of Narrowband UVB and UVA-1 Phototherapy. Lecturer, Pacific Dermatologic Association 59th Annual Meeting, San Diego, CA, August 24, 2007 and presented at UCSD Grand Rounds, 2010.

Connective Tissue Disease: Therapeutic Advances. Guest Lecturer, Calgary Society of Dermatology Grand Rounds, Calgary, Alberta, Canada, April 21, 2007.

Dermatology Pearls. Topics and Advances in Internal Medicine, Lecturer, Annual CME Course, Department of Medicine, UCSD Medical Center. San Diego, CA, February 24, 2007.

Challenging Cases. Lecturer, Forum 517, American Academy of Dermatology Summer Meeting, San Diego, CA, July 29, 2006.

Widespread Cutaneous Sarcoidosis. Lecturer, Cutaneous Manifestations of Internal Disease Forum 511, American Academy of Dermatology Summer Meeting, San Diego, CA, July 28, 2006.

Collagen Vascular Disorders in Skin of Color. Lecturer, Skin of Color Course 101, American Academy of Dermatology Summer Meeting, San Diego, CA, July 27, 2006.

Dermatologic Therapy Review, Lasers in Dermatology, Skin Signs of Systemic Disease, Bullous Diseases Symposium and Connective Tissue Disorders (5 lectures). Lecturer, Dubai Dermatology Review Course, April 17-19, 2006, Dubai, United Arab Emirates.

Psoriasis Therapeutics. Presentation to Targegen Inc. Advisory Board, San Diego, CA, March 16, 2006.

Lasers in Dermatology, Topics and Advances in Internal Medicine, Lecturer, Annual CME Course, Department of Medicine, UCSD Medical Center. San Diego, CA, March 5, 2006.

Rosacea Update. Lecturer, Forum, American Academy of Dermatology Annual Meeting, San Francisco, CA, March 3, 2006.

Therapeutic Focus on Connective Tissue Disorders. Lecturer, Focus Session: American Academy of Dermatology Annual Meetings, Washington, DC, February 3, 2007, San Francisco, CA, March 5, 2006 and New Orleans, LA, February 22, 2005.

Cutaneous Lupus. Guest Lecturer, UCSD Dermatology Grand Rounds, January 26, 2006.

Birt Hogg Dube Syndrome. Lecturer, Medical Dermatology Symposium, American Academy of Dermatology, Annual Summer Meeting, New York, NY, July 30, 2004.

Palisaded and Neutrophilic Granulomatous Dermatitis. Abstract presentation. Medical Dermatology Society Meeting. Washington, D.C., February 5, 2004.

Neonatal Lupus Erythematosus. Lecturer, Medical Dermatology Symposium, American Academy of Dermatology, Annual Summer Meeting, Chicago, IL, July 27, 2003.

Medical Dermatology. Guest lecturer: Temple University Medical Center, Department of Internal Medicine, June 9, 2003.

Rosacea Update. Lecturer, Focus Session: American Academy of Dermatology Annual Meeting, San Francisco, CA, March 21, 2003

Retinoids and Rosacea. Presentation to Johnson & Johnson Advisory Board, Philadelphia, PA, May, 2002.

Skin signs of HIV infection. Lecturer, Dermatology Core-Curriculum Course for Medical Students, University of Pennsylvania School of Medicine, Philadelphia, PA, April 23, 2002.

Pediculosis. Lecturer, Dermatology Core-Curriculum Course for Medical Students, University of Pennsylvania School of Medicine, Philadelphia, PA, April 25, 2002 and Boston University School of Medicine, Boston, MA, January 5, 2004.

Teaching for Teachers. Lecturer with Discussion Group: Dermatology Teachers Exchange Group (DTEG), Annual Meeting, Chicago, IL, October 4, 2002.

Family Practice Board Review Course: Dermatology Review. Lecturer, Renaissance Hotel, Philadelphia Airport, June 11, 2003 and July 2, 2002.

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. 4 minute talk: Gross and Microscopic Symposium. American Academy of Dermatology, New Orleans, LA, February 23, 2002.

Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Abstract presentation: Medical Dermatology Society Annual Meeting, New Orleans, LA, February 21, 2002.

Picking an Assessment Tool. Lecturer: ACGME Resident Competencies. Graduate Medical Education Committee, University of Pennsylvania, Philadelphia, PA, January 18, 2002.

Skin Signs of Systemic Disease. Lecturer, Department of Internal Medicine Noon Conference, Pennsylvania and Presbyterian Hospitals, Philadelphia, PA. November 16, 2001, January 28, 2002, November 15, 2002.

Dermatologic Emergencies. Lecturer, Department of Internal Medicine Noon Conference, Pennsylvania and Presbyterian Hospitals, Philadelphia, PA. September 24, 2001, September 14, 2001 and September 6, 2002.

ACGME Resident Competencies and the 360-Degree Global Evaluation Tool. Lecture with Discussion Group: Dermatology Teachers Exchange Group, Annual Meeting, Chicago, IL, September 7, 2001.

Cosmetic Dermatology: The Aging Face. Lecturer, Grand Rounds, Department of Dermatology, Geisinger Medical Center, Danville, PA, December 14, 2000 and Resident Lecture: University of Pennsylvania, Philadelphia, PA, January 29, 2002.

A twenty-year progression of X-linked recessive epidermodysplasia verruciformis of Lewandowsky and Lutz with review of recent molecular advances. 4 minute talk: Gross and Microscopic Symposium. American Academy of Dermatology, Washington, DC, March, 2001.

Pigmented Purpuric Dermatosis: Lecturer, Dermatology Annual CME Course, Geisinger Medical Center, Danville, PA, May 17, 2000.

Psoralen and UVA Photochemotherapy: Lecturer, Grand Rounds, Department of Dermatology, Milton S. Hershey Medical Center, Hershey, PA, December 2, 1999.

Eccrine angiomatous hamartoma Poster: Society of Pediatric Dermatology, Annual Meeting, Crystal Lake, Michigan, July, 1999.

Clinical Trials

“BI 655066 versus Ustekinumab and placebo comparators in a randomized double blind trial for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1).” Sponsor: Boehringer Ingelheim. March 2016. Principal Investigator, MedDerm Associates

“A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Asimadoline in Adult Subjects with Pruritus Associated with Atopic Dermatitis.” Sponsor: Tioga. June 2015. Principal Investigator, MedDerm Associates

“To Assess Pre- and Post-surgical study of subject and Clinician Reported Outcomes in Subjects with Hidradenitis Suppurativa.” Sponsor: Adelphi. April 2015. Principal Investigator, MedDerm Associates

“Psoriasis Registry: To study the comparative safety of approved psoriatic therapies in a national cohort of PSO subjects treated by dermatologists. To analyze the epidemiology and natural history of the disease, comorbidities, current treatment practices and comparable effectiveness.” Sponsor: Corrona. April 2015. Principal Investigator, MedDerm Associates

“X052171: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients with Pyoderma Gangrenosum.” Sponsor: XOMA. January 2015. Principal Investigator, MedDerm Associates

“X052172: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum.” Sponsor: XOMA. January 2015. Principal Investigator, MedDerm Associates

“A Phase3, Multicenter, Randomized, Double-blind Study Comparing Guselkumab and Adalimumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis CNTO1959PSO3001.” Sponsor: Janssen. October 2014. Prinicipal Investigator, MedDerm Associates

“A Phase3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis Incorporating Randomized Withdrawal and Retreatment CNTO1959PSO3002.” Sponsor: Janssen. October 2014. Principal Investigator, MedDerm Associates

“A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris” Sponsor: Allergan. November 2013. Principal Investigator. MedDerm Associates

“Concept Elicitation Interviews and Qualitative Evaluation of the DLQI in Patients with Hidradenitis Suppurativa” Sponsor: MedImmune. October 2013. Principal Investigator. MedDerm Associates

“A Multicenter Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceuticals Inc.’s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel 1.2%/2.5% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris” Sponsor: Taro Pharmaceuticals. January 2013. Principal Investigator. MedDerm Associates

“A Phase 3b. Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate a “Subject tailored” Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis” Sponsor: Janssen. June 2012. Principal Investigator. MedDerm Associates

“A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared with Placebo And Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis: AMAGINE-3.” Sponsor: Amgen. April, 2012. Principal Investigator, MedDerm Associates.

“A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After 12-weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-Term Efficacy up to One Year in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis: FIXTURE Trial.” Sponsor: Novartis. December, 2011. Principal Investigator, MedDerm Associates.

“A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects with Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus.” Sponsor: Celgene. August, 2011. Principal Investigator, MedDerm Associates.

“A Phase 3, Multi-Site, Open-Label Study of the Long Term Safety and Tolerability of 2 Oral Doses of CP-690,550 in Subjects with Moderate to Severe Chronic Plaque Psoriasis.” Sponsor: Pfizer, Inc. March, 2011. Principal Investigator, MedDerm Associates.

“A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Etanercept in Subjects with Moderate to Severe Plaque Psoriasis.” Sponsor: Amgen, Inc., May 2009. Principal Investigator, MedDerm Associates.

“Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects with Moderate to Severe Chronic Hidradenitis Suppurativa.” Sponsor: Abbott Pharmaceuticals, February, 2009. Principal Investigator, MedDerm Associates.

“Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab Therapy in Patients with Plaque Psoriasis who had an Inadequate Response to Etanercept.” PSUNRISE Trial. Sponsor: Centocor, October, 2008. Principal Investigator, MedDerm Associates.

“Multicenter, Open Registry of Patients with Psoriasis who are Candidates for Systemic Therapy including Biologics.” PSOLAR Registry. Sponsor: Centocor, April, 2008. Principal Investigator, MedDerm Associates.

“Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects who Completed a Preceding Psoriasis Study with ABT-874. M10-016. Sponsor: Abbott Pharmaceuticals, January, 2008, ongoing. Principal Investigator, MedDerm Associates.

“Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis. M06-890. Sponsor: Abbott Pharmaceuticals, January, 2008. Principal Investigator, MedDerm Associates.

“Observational Post-Marketing Safety Surveillance Registry of EnbrelTM (etanercept) for the Treatment of Psoriasis.” Observe-5 Registry. Sponsor: Amgen, May, 2007. Principal Investigator, MedDerm Associates.

“Acne Free vs. Proactiv for the Treatment of Moderately Severe Acne Vulgaris.” Cosmeceutical. Sponsor: University Medical, Inc., August, 2006. Principal Investigator, MedDerm Associates.

“Acne Free vs. Proactiv for the Treatment of Mild to Moderate Acne Vulgaris.” Cosmeceutical. Sponsor: University Medical, Inc., April, 2006. Independently-contracted physician-investigator, PRACS research institute, San Diego, CA.

“Pulsed Dye Laser as Adjunctive Therapy for Discoid Lupus Erythematosus.” Investigator initiated pilot trial, 2002. Site: University of Pennsylvania, Department of Dermatology. Principal Investigator.

“Sub-Antimicrobial-Dose Doxycycline for the Treatment of Papulopustular Rosacea.” Investigator initiated pilot trial, 2002. Site: University of Pennsylvania, Department of Dermatology. Principal Investigator: Michelle Pelle, M.D.

“Minimal Erythema Dose (MED) testing to Predict Narrowband UVB Dosing in Patients with Light-Responsive Dermatoses”. Investigator initiated review, 2002. Site: University of Pennsylvania, Department of Dermatology. Retrospective review of patients attending University-based Phototherapy Center. Primary Investigator: Abby Van Voorhees, M.D. My role: data collection.

“Treatment of refractory atopic dermatitis with low dose oral cyclosporine.” Investigator-initiated trial, 2001. Site Geisinger Medical Center Department of Dermatology. Principal Investigator: Michelle Pelle, MD.

“Apligraf for the Treatment of Venous Leg Ulcers.” Phase IV trial. Sponsor: Novartis Pharmaceuticals, 2000-2001. Site: Geisinger Medical Center Department of Dermatology. Sub-investigator.

Research Training

GRAPPA Training and certification, 2016.

PASI and NAPSI Training Course and Certification. 2007.

National Cancer Institute Human Participant Protections Education for Research Teams Completion Certificate, September 2006.

International Psoriasis Council Education Symposium: Running Dermatology Clinical Trials, Scottsdale, Arizona, March 11-13, 2005.

Acne and rosacea Inflammatory Lesion Count Training, 2003.

Alternative Media

Dermatology Update, Video Series Feature: Rosacea., AAD Media Relations, October, 2004.

Pelle MT. Online Continuing Medical Education Lecture Series, Graduate Education Foundation:

1. “Cutaneous Neoplasms Part 1 and Part 2”, released July, 2005.
2. “Inflammatory Dermatoses”, released December, 2005.
3. “Cutaneous Manifestations of Infection”, in production.
4. “Skin Signs of Systemic Disease”, in production.

Pelle MT, Brown S. Rosacea Update. Dialogues in Dermatology. Compact Disc Presentation. June, 2004.

Pelle MT, James WD. Online Resident Evaluation System: 360-degree evaluation and monthly rotation evaluation, in accordance with ACGME guidelines. http://uphsdrm1.uphs.upenn.edu/evaluations/evaluations.aspx